The central hypothesis of this proposal is that there is a subgroup of malignant human gliomas (MHG) in which the neoplastic cells gain a growth advantage over non-neoplastic cells by increased expression of the epidermal growth factor receptor (EGFR). EGFR expression will be determined in a large series of MHG biopsies, permanent MHG-derived cell lines and athymic mouse-grown MHG. Molecular and chromosomal analyses will define the mechanisms of increased EGFR expression and will determine if the amplified and/or rearranged genes are in double minute chromosomes, homogeneously staining regions, abnormally banded regions, or chromosomal translocations.
Specific aims of this proposal are: (1) Antibodies against the EGFR will be used immunohistochemically on biopsied MHG, permanent MHG-derived cell lines, and MHG serially passaged in athymic mice to confirm that glioma cells express these receptors. Competition radioimmunoassay and epidermal growth factor (EGF) binding assays will be used to determine the range in level of receptor expression exhibited by these tumors, cell lines, and mouse-grown lines. 2) Immunoblot analysis, immunoprecipitation and autophosphorylation will be used to determine if the molecules detected in the immunologic studies are intact, functional EGFR or are EGFR-related proteins. 3) The mechanism of increased EGFR expression in the tumors, cell lines and mouse-grown tumors identified in Specific Aim (1) will be defined by assessing gene amplification, gene rearrangement, and gene transcription using a c-DNA probe against the EGFR in Southern and Northern blotting. 4) Since the panel of glioma biopsies, glioma-derived cell lines and athymic mouse-grown tumors which is available has been karyotyped, it will be possible to determine which of the gross chromosomal abnormalities, seen in these tumors, are associated with which mechanisms of increased expression. In situ hybridization will be performed on prophase and metaphase chromosomes from these specimens to confirm the location of amplified or translocated EGFR genes. If MHG cells differ from non-neoplastic cells by either quantitative or qualitative differences in EGFR expression, antibodies, polypeptides or other molecules which bind the EGFR could be used either alone or carrying toxic substances to retard tumor growth. Since the frequency and level of increased EGFR expression will be determined for MHG and the chromosomal and molecular mechanisms of enhancement of this gene product will be defined, the proposed studies will provide the theoretical basis for such therapeutic approaches. These experiments will also identify MHG cell lines and athymic mouse-grown tumors with high EGFR production which could be used for testing anti-EGFR agents in in vitro and in vivo systems.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA043722-02
Application #
3186026
Study Section
Pathology A Study Section (PTHA)
Project Start
1987-01-01
Project End
1990-12-31
Budget Start
1988-01-01
Budget End
1988-12-31
Support Year
2
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Duke University
Department
Type
Schools of Medicine
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705
McLendon, Roger E; Herndon 2nd, James E; West, Bryan et al. (2005) Survival analysis of presumptive prognostic markers among oligodendrogliomas. Cancer 104:1693-9
Rasheed, B K; McLendon, R E; Herndon, J E et al. (1994) Alterations of the TP53 gene in human gliomas. Cancer Res 54:1324-30
Fuller, G N; Bigner, S H (1992) Amplified cellular oncogenes in neoplasms of the human central nervous system. Mutat Res 276:299-306
Rasheed, B K; Fuller, G N; Friedman, A H et al. (1992) Loss of heterozygosity for 10q loci in human gliomas. Genes Chromosomes Cancer 5:75-82
Bigner, S H (1990) Molecular probes in neuro-oncology: the future. Cancer Invest 8:445-6
Fuchs, H E; Archer, G E; Colvin, O M et al. (1990) Activity of intrathecal 4-hydroperoxycyclophosphamide in a nude rat model of human neoplastic meningitis. Cancer Res 50:1954-9
Bigner, S H; Mark, J; Bigner, D D (1990) Cytogenetics of human brain tumors. Cancer Genet Cytogenet 47:141-54
Fredman, P; Mansson, J E; Bigner, S H et al. (1990) Gangliosides in the human glioma cell line U-118 MG grown in culture or as xenografts in nude rats. Biochim Biophys Acta 1045:239-44
Bigner, S H; Schold, S C; Friedman, H S et al. (1989) Chromosomal composition of malignant human gliomas through serial subcutaneous transplantation in athymic mice. Cancer Genet Cytogenet 40:111-20
Rosenberg, M C; Colvin, O M; Griffith, O W et al. (1989) Establishment of a melphalan-resistant rhabdomyosarcoma xenograft with cross-resistance to vincristine and enhanced sensitivity following buthionine sulfoximine-mediated glutathione depletion. Cancer Res 49:6917-22

Showing the most recent 10 out of 17 publications